Atea Pharmaceuticals, Inc. (AVIR)
|Net Income (ttm)||35.29M|
|Day's Range||11.73 - 12.77|
|52-Week Range||10.76 - 94.17|
|Price Target||16.67 (+31.0%)|
|Est. Earnings Date||Nov 11, 2021|
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed ... [Read more...]
Financial PerformanceFinancial Statements
According to 3 analysts, the average rating for AVIR stock is "Strong Buy." The 12-month stock price forecast is 16.67, which is an increase of 30.95% from the latest price.
A mid-stage trial miss caused investors to hit the exits this week.
Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.
The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.
Atea Pharmaceuticals (AVIR) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. The post AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Phar...
Atea Pharma's Covid antiviral misses mark in mid-stage trial
CNBC's Meg Tirrell joins 'Squawk Box' to report on Atea Pharmaceuticals' Roche-partnered Covid-19 antiviral, which missed its primary goal in a phase 2 trial.
(Reuters) -A mid-stage trial testing Atea Pharmaceuticals' COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in non-hospitalized patients with mild or moderate d...
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related: Atea Unveils Trial Am...
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatie...
Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms
These stocks could be attractive at discounted prices.
This biotech's experimental COVID-19 medication could be a big winner.
BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executi...
Orally administered treatments of COVID-19 infections are coming into focus as vaccine stocks lose their luster.
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executi...
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against...
BOSTON, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced the publication of data demonstrating the in vit...
You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught app...
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and aud...
An effective oral antiviral therapy for the coronavirus may be around the corner.
BOSTON, July 12, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for...
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche Holding AG (OTC: RHH...
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license agreement with Roche Holding AG (OTC: RHHBY...